Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call highlights a mixed financial performance with strong revenue growth in Battery & Energy Products but significant challenges in Communications Systems. Operational inefficiencies, delays in government contracts, and a net loss due to impairment charges weigh negatively. The Q&A section reveals management's lack of clarity on timelines for key projects, adding uncertainty. Despite some positive aspects like backlog growth and new medical orders, the overall sentiment is negative, especially given the financial losses and strategic risks.

Key Financial Performance

Q4 Revenue $48.5 million, an increase of 10.6% year-over-year, driven by strong performance in the Battery & Energy Products segment.

Full Year 2025 Revenue $191.2 million, a growth of 16.2% year-over-year, with over $30 million from new products less than 5 years old.

Battery & Energy Products Segment Revenue (Q4) $45.9 million, a 15.1% increase year-over-year, driven by a 39.6% increase in medical, 20.4% increase in industrial and other commercial, and a 1.2% increase in government defense, partially offset by a 3.6% decrease in oil and gas market sales.

Communications Systems Segment Revenue (Q4) $2.6 million, a decline of 35.2% year-over-year, primarily due to timing of expected orders delayed by the U.S. government shutdown.

Consolidated Gross Profit (Q4) $12.1 million, up 13.7% year-over-year, with a gross margin of 24.9%, a 70 basis point improvement from the prior year.

Battery & Energy Products Gross Profit (Q4) $11.5 million, a 23.7% increase year-over-year, with a gross margin of 25.1%, a 170 basis point increase due to product mix and higher factory cost absorption.

Communications Systems Gross Profit (Q4) $0.5 million, down from $1.3 million in the prior year, with a gross margin of 19.9%, a decline from 31.9% due to lower factory volume.

Operating Loss (Q4) $10.6 million, reflecting a $12.2 million noncash intangible asset impairment charge and onetime costs, compared to an operating income of $1.5 million in the prior year.

Net Loss (Q4) $7.4 million or $0.45 per share, compared to net income of $0.2 million or $0.01 per share in the prior year, primarily due to the intangible asset impairment charge.

Adjusted EBITDA (Q4) $5.7 million or 11.7% of sales, compared to $3.9 million or 8.9% of sales in the prior year.

Backlog (End of Q4) $110.2 million, an increase of $20 million or 22.1% from the prior quarter, representing 58% of TTM sales.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Revenue from new products: Over $30 million from new products less than 5 years old, representing a growth of 16.2% year-over-year.

New product launches: Several new products slated for release in 2026, including the A-2303 amplifier, Crescent man wearable compute solution, and 19 amp-hour Thin Cell.

Conformal wearable battery: Production quantities have begun shipping, with additional orders in backlog for 2026.

Medical cart power system: Released the X5-SuperLite, a USB-C hot-swappable power system, now in production with initial orders for 2026.

Market expansion in ruggedized computing: Focus on ruggedized server cases and new server variants for military programs.

International sales growth: Increased international sales split from 29% to 38% year-over-year, driven by the acquisition of Electrochem.

Operational cost reduction: Closed 2 smaller manufacturing facilities in North America, reducing locations from 7 to 5.

Vertical integration: Incorporated Electrochem cells into existing pack assemblies, broadening the addressable market.

Operational efficiency initiatives: Brought in external consultants and new leadership to address inefficiencies and improve gross margins.

Rebranding efforts: Transitioned to a unified Ultralife master brand to reduce redundant costs and align messaging.

Facility realignment: Aligned several Battery & Energy facilities under single leadership to maximize synergies.

Focus on strategic projects: Prioritized converting long-term development efforts into revenue and advancing vertical integration.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Uncertain global economic conditions: The company acknowledges that uncertain global economic conditions could adversely impact its performance, operations, or strategic objectives.

Reductions in revenues from key customers: Potential reductions in revenues from key customers are highlighted as a risk that could negatively affect the company's financial performance.

Delays or reductions in U.S. and foreign military spending: The company identifies delays or reductions in military spending as a risk that could impact its operations and revenue.

Acceptance of new products on a global basis: Challenges in achieving global acceptance of new products are noted as a potential risk to the company's growth and strategic objectives.

Disruptions or delays in supply of raw materials and components: The company mentions risks related to disruptions or delays in the supply chain, including raw materials and components, due to factors like global conflicts, weather, or other uncontrollable events.

Decline in Communications Systems segment revenue: The Communications Systems segment experienced a 35.2% revenue decline due to delayed U.S. government orders, highlighting risks related to dependency on government contracts.

Recurring yield issues and inefficiencies in Newark operations: Operational inefficiencies and recurring yield issues in the Newark facility are identified as challenges impacting gross margins and operational performance.

Complex and confusing brand architecture: The company acknowledges that its complex brand architecture creates customer confusion and redundant costs, posing a challenge to operational efficiency and market positioning.

Dependency on large development projects: The company is reliant on long-term development projects, which could pose risks if these projects face delays or fail to meet expectations.

Cyber insurance claim and legal fees: Legal fees associated with a cyber insurance claim are noted as a one-time cost, indicating potential risks related to cybersecurity incidents.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Communication Systems Business: Expected to rebound in 2026 with new product sales and long-delayed programs starting to sell through. Focus on profitability and growth with several new products in the commercial capture phase and multiple new products slated for release in 2026. Engaged with partners on large programs of record and long-term projects for recurring baseline revenue.

Battery & Energy Business: Anticipated improvement in gross margin and revenue from new product launches in 2026. Focus on addressing recurring yield issues and inefficiencies with external consultants and new leadership. Revised pricing and ongoing cost-down projects with customers. Expansion of vertical integration opportunities enabled by the Electrochem acquisition.

Backlog and Revenue: Backlog of $110 million exiting 2025, with virtually all expected to ship in 2026. Includes over $6 million driven by new products released in 2025.

New Product Development: Continued investment in new products to drive revenue and organic growth. Focus on ruggedized server cases, DC power supply enhancements, and wearable compute solutions in the Communication Systems segment. Development of conformal wearable batteries, thin cell technology, and medical cart power options in the Battery & Energy segment.

Medical OEM Partnership: Production orders received for a battery pack for a new pump application, with shipments starting mid-2026 as the customer ramps device manufacturing.

Thin Cell Technology: Initial production capabilities established for medical wearable sector and item tracking applications. Sales pipeline strengthening with new projects in qualification phase. Additional development efforts to reduce thickness and manufacturing complexity for large-scale automation.

Medical Cart Power Options: X5-SuperLite USB-C hot-swappable power system completed certifications and is in production. Initial production orders received for 2026 shipment.

Operational Efficiency: Focus on converting long-term development efforts into revenue, advancing vertical integration, and maintaining operational efficiency initiatives. Reduced North American facility count and unified back-office systems across most of North America.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:What are the company's goals in terms of organic growth rate and EBITDA margin?

A:The company is targeting to achieve a minimum of 2x GDP in organic growth. Short-term, they aim for greater than 10% EBITDA, with aspirations for higher margins in the long term. They also plan to explore further growth opportunities after paying down debt from their last acquisition.

Q:What is the definition of baseline revenue for the Comm Systems business?

A:Baseline revenue for the Comm Systems business is defined as $25 million. There are also opportunities for large orders, such as Joint Fires, which is moving from the R&D stage to the solicitation stage.

Q:What is the status and potential of the new medical order?

A:The new medical order is with an OEM the company has worked with for years. It is expected to generate a 6-figure plus revenue annually and is in the product launch phase. However, the company has experienced delays in other medical projects, such as thin cell, where revenue is still pending.

Q:Review of Unclear Management Responses

A:Management appeared to avoid providing a direct answer regarding the timeline for revenue realization from the thin cell medical projects. They acknowledged delays but did not offer specific details or a clear timeline for resolution.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

ULBI Transcript

Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript

Unknown3-10

Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript

Unknown11-18

The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.

Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript

Unknown8-8

The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.

Ultralife Corporation (NASDAQ:ULBI) Q1 2025 Earnings Call Transcript

Unknown5-11

The earnings call reveals mixed signals. While revenue grew 21% YoY, operating income and EPS decreased due to increased expenses and acquisition costs. Strong government-defense sales were offset by declines in other segments. The Q&A highlighted concerns over tariffs and vague management responses, but also noted confidence in transformational projects and steady medical markets. Despite no share repurchase program, the backlog and working capital indicate demand and liquidity. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement in either direction.

ULBI Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.